Article thumbnail

Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy

By Tristan M. Sissung, Romano Danesi, C. Tyler Kirkland, Caitlin E. Baum, Sandra B. Ockers, Erica V. Stein, David Venzon, Douglas K. Price and William D. Figg

Abstract

ERα and CYP19 polymorphisms affect the therapeutic outcome of docetaxel in patients with castrationresistant prostate cancer (CRPC) and are associated with CRPC risk

Topics: JCEM Online: Brief Reports
Publisher: Endocrine Society
OAI identifier: oai:pubmedcentral.nih.gov:3048329
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles